Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14380
Abstract: BACKGROUND There is a lack of clinically available predictive models for patients with epidermal growth factor receptor (EGFR) mutation positive, advanced non-small cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs). METHODS The clinical… read more here.
Keywords: cancer; progression free; mutation; egfr mutation ... See more keywords
The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.16222
Abstract: Purpose The outcome of pretreatment epidermal growth factor receptor (EGFR) T790M mutation in EGFR mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) is controversial, this study aimed to evaluate… read more here.
Keywords: role pretreatment; patients treated; treated egfr; t790m mutation ... See more keywords
Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer"
DOI: 10.7150/jca.33450
Abstract: Background: Response Evaluation Criteria in Solid Tumors (RECIST) has been widely utilized to evaluate new therapeutic strategies in cancer. However, RECIST fails to assess the heterogeneity of response in highly active therapies. Depth of response… read more here.
Keywords: response; depth response; treated egfr; cancer ... See more keywords